NTRK3 and metastatic neoplasm: Most patients had metastatic disease (90.6%, 96.3%, resp., p = 0.23) at baseline, and NTRK1 (44.4%, 40.5%, resp., p = 0.70) and NTRK3 (53.0%, 56.8%, resp., p = 0.72) were the most common NTRK gene fusions.